BRIEF published on 08/11/2026 at 18:35, 1 month 15 days ago Medincell at Piper Sandler CNS Symposium 2026 Investors Medincell BEPO Technology Piper Sandler CNS Symposium Prolonged Treatments
BRIEF published on 08/11/2026 at 18:35, 1 month 15 days ago Medincell au Piper Sandler CNS Symposium 2026 Investisseurs Medincell Piper Sandler CNS Symposium BEPO Technologie Traitements Prolongés
PRESS RELEASE published on 08/11/2026 at 18:30, 1 month 15 days ago Informations privilégiées / Autres communiqués Medincell participera au Piper Sandler CNS Symposium le 13 août 2026 avec le Dr Grace Kim, CSO, U.S. Finance. L'entreprise développe des traitements injectables à action prolongée pour divers domaines thérapeutiques Medincell Dr Grace Kim Action Prolongée Piper Sandler CNS Symposium Traitements Injectables
BRIEF published on 07/29/2026 at 13:29, 1 month 29 days ago Medincell Partner Teva Reports Strong UZEDY® Sales Growth Net Sales Growth Revenue Outlook Schizophrenia Treatment Teva Pharmaceuticals Long-acting Injectable
BRIEF published on 07/29/2026 at 13:29, 1 month 29 days ago Record sales for UZEDY® in the second quarter of 2026 Schizophrenia Teva Pharmaceuticals UZEDY Sales 2026 Forecast Medincell Royalties
BRIEF published on 07/29/2026 at 13:29, 1 month 29 days ago Ventes record pour UZEDY® au deuxième trimestre 2026 Schizophrénie Teva Pharmaceuticals Ventes UZEDY Prévisions 2026 Royalties Medincell
BRIEF published on 07/29/2026 at 13:29, 1 month 29 days ago Le partenaire de Medincell, Teva, annonce une forte croissance des ventes d'UZEDY® Croissance Des Ventes Nettes Traitement De La Schizophrénie Perspectives De Revenus Teva Pharmaceuticals Injectable À Action Prolongée
PRESS RELEASE published on 07/29/2026 at 13:24, 1 month 29 days ago Inside Information / Other news releases Teva's UZEDY® achieves record Q2 net sales of $77M, up 43% YoY. Olanzapine LAI FDA action anticipated in Q4 2026. Medincell's innovative long-acting injectable treatments show promising results Record Sales Medincell Teva UZEDY Long-acting Injectable
PRESS RELEASE published on 07/29/2026 at 13:24, 1 month 29 days ago Informations privilégiées / Autres communiqués Ventes record d'UZEDY® de 77 M$ au 2ème trimestre 2026 (+43% sur un an), Teva relève ses prévisions. Annonce sur les résultats de Teva : ir.tevapharm.com Schizophrénie Ventes Record Teva Pharmaceuticals UZEDY® Prévisions 2026
BRIEF published on 07/28/2026 at 20:26, 1 month 29 days ago Publication of the 2025/2026 Universal Registration Document by Medincell Financial Report General Assembly CSR Registration Document Medincell
Published on 09/26/2026 at 01:00, 1 day 14 hours ago Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 1 day 17 hours ago Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 1 day 22 hours ago Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 2 days ago HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/26/2026 at 15:30, 1 day ago QUORRA X5 fait ses débuts mondiaux à REHACARE International 2026 en Allemagne
Published on 09/26/2026 at 15:30, 1 day ago QUORRA X5 Makes Its Global Debut at REHACARE International 2026 in Germany
Published on 09/26/2026 at 15:15, 1 day ago Timur Turlov Elected FIDE President, Becomes First Kazakh to Lead World Chess
Published on 09/26/2026 at 07:45, 1 day 7 hours ago Green SM Begins Pilot Operations In The Netherlands, Further Expanding Its Presence In Europe
Published on 09/26/2026 at 00:01, 1 day 15 hours ago Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia
Published on 09/25/2026 at 17:45, 1 day 21 hours ago COGRA : ASSEMBLÉE GÉNÉRALE MIXTE DU 16 OCTOBRE 2026 / MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025/2026
Published on 09/25/2026 at 17:40, 1 day 22 hours ago Availability of the 2026 half-year financial report
